Adicet Bio Inc Ordinary Shares ACET
News
Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference
Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Adicet Bio Gets FDA Clearance For Phase 1 Trial of Prostate Cancer Treatment
Adicet Bio Announces FDA Clearance of IND Application for ADI-212
Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference
